Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia

Journal of Neural Transmission

Volumn 122, Issue , 2015, Pages 111-122

  Al Awam, Khaled ^a,b   Haußleiter, Ida Sibylle ^c   Dudley, Ed ^a   Donev, Rossen ^a   Brüne, Martin ^c   Juckel, Georg ^c   Thome, Johannes ^a,d  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b Kuwait Centre for Mental Health   (Kuwait)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Biomarker; Metabolomics; Protein profiling; Proteomics; Schizophrenia

Indexed keywords

2 PIPERIDINE CARBOXYLIC ACID; 6 DEOXY MANNOFURANOSE; AMISULPRIDE; ARIPIPRAZOLE; BIOLOGICAL MARKER; CHLORPROTHIXENE; CHOLESTEROL; CLOZAPINE; FATTY ACID; FLUPENTIXOL; GALACTOSEOXIME; HALOPERIDOL; LEVOMEPROMAZINE; M/Z 3177 PEPTIDE; MELPERONE; OLANZAPINE; PALIPERIDONE; PHOSPHOLIPID; PROMETHAZINE; PROTEIN; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG; ZUCLOPENTHIXOL; LIPID; PLASMA PROTEIN; PROTEOME;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE DURATION; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HYDROPHOBICITY; LIPID BLOOD LEVEL; MALE; METABOLOMICS; MIDDLE AGED; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; YOUNG ADULT; AGED; BLOOD; CASE CONTROL STUDY; MASS SPECTROMETRY; METABOLISM; METABOLOME; PHYSIOLOGY; PROCEDURES;

ADULT; AGED; BLOOD PROTEINS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; LIPIDS; MALE; METABOLOME; MIDDLE AGED; PROTEOME; PROTEOMICS; ROC CURVE; SCHIZOPHRENIA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; YOUNG ADULT;

EID: 84938970246     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-014-1224-0     Document Type: Article

References (40)

1. Al Awam K, Dudley E, Donev R, Thome J (2012) Protein and peptide profiling as a tool for biomarker discovery in depression. Electrophoresis 33(24):3830–3834
2. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders (4th ed., textrev.). American Psychiatric Press, Washington, DC
3. Berger GE, Smesny S, Amminger GP (2006) Bioactive lipids in schizophrenia. Int Rev Psychiatry 18(2):85–98
4. Bicikova M, Hill M, Ripova D, Mohr P, Hampl R (2013) Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia. J Steroid Biochem Mol Biol 133:77–83
5. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95
6. Budczies J, Denkert C, Müller BM, Brockmöller SF, Klauschen F, Györffy B, Dietel M, Richter-Ehrenstein C, Marten U, Salek RM, Griffin JL, Hilvo M, Orešič M, Wohlgemuth G, Fiehn O (2012) Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue—a GC-TOFMS based metabolomics study. BMC Genom 13:334–344
7. Diz AP, Carvajal-Rodríguez A, Skibinski DO (2011) Multiple hypothesis testing in proteomics: a strategy for experimental work. Mol Cell Proteomics 10(3):M110.004374
8. Domenici E, Willé DR, Tozzi F, Prokopenko I, Miller S, McKeown A, Brittain C, Rujescu D, Giegling I, Turck CW, Holsboer F, Bullmore ET, Middleton L, Merlo-Pich E, Alexander RC, Muglia P (2010) Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 5(2):e9166
9. Dudley E, Hässler F, Thome J (2011) Profiling for novel proteomics biomarkers in neurodevelopmental disorders. Expert Rev Proteomics 8(1):127–136
10. Estrada R, Yappert MC (2004) Regional phospholipid analysis of porcine lens membranes by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Mass Spectrom 39(12):1531–1540
11. Falkai P, Mike O, Inez MG, Paul H, Andras BG, Sophia F, MEOS Consortium (2008) A roadmap to disentangle the molecular etiology of schizophrenia. Eur Psychiatry 23(4):224–232
12. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226(1):497–509
13. Gonzalez-Burgos G, Fish KN, Lewis DA (2011) GABA neuron alterations, cortical circuit dysfunction and cognitive deficits in schizophrenia. Neural Plast. 723184 (Epub)
14. Gutiérrez MC, Delgado-Coello BA (1989) Influence of pipecolic acid on the release and uptake of [3H]GABA from brain slices of mouse cerebral cortex. Neurochem Res 14(5):405–408
15. He Y, Yu Z, Giegling I, Xie L, Hartmann AM, Prehn C, Adamski J, Kahn R, Li Y, Illig T, Wang-Sattler R, Rujescu D (2012) Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry 2:e149
16. Huang JT, Wang L, Prabakaran S, Wengenroth M, Lockstone HE, Koethe D, Gerth CW, Gross S, Schreiber D, Lilley K, Wayland M, Oxley D, Leweke FM, Bahn S (2008) Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatry 13(12):1118–1128
17. Jaros JA, Martins-de-Souza D, Rahmoune H, Rothermundt M, Leweke FM, Guest PC, Bahn S (2012) Protein phosphorylation patterns in serum from schizophrenia patients and healthy controls. J Proteomics 5(76):43–55
18. Krakowski M, Czobor P (2011) Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol. Schizophr Res 130(1–3):27–33
19. La YJ, Wan CL, Zhu H, Yang YF, Chen YS, Pan YX, Feng GY, He L (2007) Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients. J Neural Transm 114(5):657–663
20. Levin Y, Wang L, Schwarz E, Koethe D, Leweke FM, Bahn S (2010) Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Mol Psychiatry 15(11):1088–1100
21. Martins-De-Souza D, Wobrock T, Zerr I, Schmitt A, Gawinecka J, Schneider-Axmann T, Falkai P, Turck CW (2010) Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 d-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J Biol Psychiatry 11(5):719–728
22. Meister L, Alawam K, Dudley E, Taurines R, Müller SE, Walter M, Höppner J, Teipel S, Donev RM, Eckert A, Wiesbeck GA, Thome J (2011) Pilot study of the application of magnetic bead protein profiling to the study of biomarkers in addiction research. World J Biol Psychiatry 12(1):80–84
23. Mueser KT, McGurk SR (2004) Schizophrenia. Lancet 363(9426):2063–2072
24. Nishio H, Giacobini E (1981) Brain uptake of pipecolic acid, amino acids, and amines following intracarotid injection in the mouse. Neurochem Res 6(8):835–845
25. Orešič M, Tang J, Seppänen-Laakso T, Mattila I, Saarni SE, Saarni SI, Lönnqvist J, Sysi-Aho M, Hyötyläinen T, Perälä J, Suvisaari J (2011) Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med 3(3):19
26. Orešič M, Seppänen-Laakso T, Sun D, Tang J, Therman S, Viehman R, Mustonen U, van Erp TG, Hyötyläinen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lönnqvist J, Cannon TD (2012) Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med 4(1):1
27. Ray P, Manach YL, Riou B, Houle TT (2010) Statistical evaluation of a biomarker. Anesthesiology 112:1023–1040
28. Roser M, Josic D, Kontou M, Mosetter K, Maurer P, Reutter W (2009) Metabolism of galactose in the brain and liver of rats and its conversion into glutamate and other amino acids. J Neural Trans 116(2):131–139
29. Rowland LM, Kontson K, West J, Edden RA, Zhu H, Wijtenburg SA, Holcomb HH, Barker PB (2013) In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull 39(5):1096–1104
30. Schmidt-Glenewinkel T, Nomura Y, Giacobini E (1977) The conversion of lysine into piperidine, cadaverine, and pipecolic acid in the brain and other organs of the mouse. Neurochem Res 2(6):619–937
31. Schwarz E, Whitfield P, Nahnsen S, Wang L, Major H, Leweke FM, Koethe D, Lio P, Bahn S (2011) Alterations of primary fatty acid amides in serum of patients with severe mental illness. Front Biosci 3:308–314
32. Stan AD, Lewis DA (2012) Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies. Curr Pharm Biotechnol 13(8):1557–1562
33. Störber G, Ben-Shachar D, Cardon M, Falkai P, Fonteh AN, Gawlik M, Glenthoj BY, Grünblatt E, Jablensky A, Kim YK, Kornhuber J, McNeil TF, Müller N, Oranje B, Saito T, Saoud M, Schmitt A, Schwartz M, Thome J, Uzbekov M, Durany N, Riederer P (2009) Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry 10(2):127–155
34. Taurines R, Dudley E, Conner AC, Grassl J, Jans T, Guderian F, Mehler-Wex C, Warnke A, Gerlach M, Thome J (2010) Serum protein profiling and proteomics in autistic spectrum disorder using magnetic bead-assisted mass spectrometry. Eur Arch Psychiatry Clin Neurosci 260(3):249–255
35. Taurines R, Dudley E, Grassl J, Warnke A, Gerlach M, Coogan AN, Thome J (2011) Proteomic research in psychiatry. J Psychopharmacol 25(2):151–196
36. Tiss A, Smith C, Menon U, Jacobs I, Timms JF, Cramer R (2010) A well-characterised peak identification list of MALDI MS profile peaks for human blood serum. Proteomics 10(18):3388–3392
37. Van Os J, Kenis G, Rutten BP (2010) The environment and schizophrenia. Nature 468(7321):203–212
38. Vila-Rodriguez F, Honer WG, Innis SM, Wellington CL, Beasley CL (2011) ApoE and cholesterol in schizophrenia and bipolar disorder: comparison of grey and white matter and relation with APOE genotype. J Psychiatry Neurosci 36(1):47–55
39. Woods AG, Sokolowska I, Taurines R, Gerlach M, Dudley E, Thome J, Darie CC (2012) Potential biomarkers in psychiatry: focus on the cholesterol system. J Cell Mol Med 16(6):1184–1195
40. Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L (2011) Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res 10(12):5433–5443